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Background: Implantable cardioverter-deﬁbrillators (ICDs) have been established for primary and sec-
ondary prevention of fatal arrhythmias. However, little is known about the inﬂuence of ICD indications
on quality of life (QOL) and psychological disturbances. This study aimed to examine whether there were
differences in QOL and psychological distress in patients that have an ICD for primary or secondary
prevention of fatal arrhythmias.
Methods: A multicenter survey of 179 consecutive outpatients (29.1% primary prevention) with ICD
implantations completed the Short Form-8 (SF-8), Beck Depression Inventory (BDI), Impact of Event
Scale-Revised (IES-R), State-Trait Anxiety Inventory (STAI), and Worries about ICD (WAICD).
Results: Patients with an ICD for primary prevention had a higher trait anxiety score and worries about
ICD score than patients with an ICD for secondary prevention (41.7712.4 vs. 34.7712.3, p¼0.001 and
39.6718.0 vs. 30.0718.9, p¼0.002, respectively), even after adjusting for demographic and clinical
characteristics. In multivariable analysis of variance, primary prevention ICD recipients reported a poorer
QOL on the vitality subscale of the SF-8.
Conclusions: In our study population, which mostly consisted of New York Heart Association (NYHA)
class I and II subjects, primary prevention ICD recipients were more prone to experience worries about
their ICD, anxiety, and a poorer QOL compared to secondary prevention ICD recipients. In clinical
practice, primary prevention ICD patients should be closely monitored. If warranted, they should be
offered psychological intervention, as anxiety and low QOL were predictors of mortality.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
The implantable cardioverter-deﬁbrillator (ICD) is well-
established as the superior choice compared to anti-arrhythmic
drugs for the prevention of sudden cardiac death (SCD) [1,2]. The
use of ICDs has been expanded to certain patient populations whoblished by Elsevier B.V. All rights
Sciences, Kyushu University,
hi, Higashi-ku, Fukuoka-city,
A. Chishaki).have either survived an episode of life-threatening ventricular
arrhythmia (secondary prevention) or who are at risk for ven-
tricular arrhythmia (primary prevention) [2]. Although acceptance
of the device is generally high among patients and their families,
quality of life (QOL) and psychosocial issues associated with use of
an ICD deserve greater attention [3]. Anxiety, depression, anger,
and fear are the most common psychosocial responses after ICD
implantation [3,4]. Nearly half of the patients with an ICD have
depression and anxiety [5].
SCD occurs in approximately 40 cases per every 100,000 per-
sons annually in each country of Asia [6]. A previous study showedreserved.
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Registry demonstrated a signiﬁcant increase in the utilization of
prophylactic ICDs [7]. Paradoxically, limited data exist regarding
the effect of ICD indications on QOL and psychological distress in
Japanese patients. A previous study suggested that there was no
evidence to suggest that patients receiving an ICD for primary
prophylaxis had a subsequently poorer QOL and greater distress
than patients receiving an ICD for secondary prophylaxis [8].
However, patients identiﬁed to receive an ICD for primary pro-
phylaxis differ from patients who receive the device for secondary
prevention. In particular, primary prophylaxis patients may fail to
understand why they need the device. In relation to health-related
QOL, one study found that the QOL did not signiﬁcantly differ
between primary and secondary prevention ICD recipients [9].
Another study showed no differences in mean depression and
mean anxiety scores between primary and secondary prevention
ICD patients [5].
The aims of this study were to examine (1) whether primary
prevention ICD recipients were at a greater risk for increased
anxiety, depression, post-traumatic stress disorder (PTSD), and
worries about their ICD, and (2) whether primary prevention ICD
recipients had poorer health-related QOL compared to secondary
prevention ICD recipients, adjusting for demographic and clinical
characteristics.2. Materials and methods
2.1. Patients and study design
In this cross-sectional research study, we examined 179 out-
patients with ICDs based on our previous study [10]. Patients were
recruited consecutively and the survey was given once during an
outpatient clinic visit. The eligibility criteria were as follows:
patients who had an ICD implanted, were aged 418 years, were
judged capable of completing the survey physically and cogni-
tively, and were capable of understanding spoken and written
Japanese. All patients were given information about this study and
provided written informed consent. The institutional review board
and ethics committee of Kyushu University Graduate School of
Medical Sciences and Tokyo Metropolitan Hiroo Hospital approved
this study (IRB approval number #258, approval date July 6, 2005).
2.2. Measures
2.2.1. Demographic and clinical variables
Demographic variables included sex and age. Information on
clinical variables, including left ventricular ejection fraction (LVEF),
presence of appropriate shocks (with and without syncope),
presence of inappropriate shocks, comorbidities (including
hypertension, stroke, systemic embolization, diabetes mellitus,
dyslipidemia, and renal failure), medications, device-related
complications (including presence of inappropriate shocks, pul-
monary embolization, and device infection), and the predominant
cardiac diagnosis were obtained from the medical records. Dura-
tion of ICD therapy and shock frequency were also collected via
the medical records. The predominant cardiac diagnoses consisted
of myocardial infarction, dilated cardiomyopathy, hypertrophic
cardiomyopathy, Brugada syndrome, cardiac sarcoidosis, valvular
heart disease, arrhythmogenic right ventricular dysplasia (ARVD),
myocarditis, angina pectoris, long QT syndrome, and hypertensive
heart disease.
The indication for ICD use was deﬁned retrospectively using
certain criteria. Primary prevention of SCD refers to the use of ICDs
in individuals who are at risk for, but have not yet had an episode
of sustained ventricular tachycardia (VT), ventricular ﬁbrillation, orresuscitated cardiac arrest. Secondary prevention refers to pre-
vention of SCD in patients who survived a prior sudden cardiac
arrest or sustained VT [11,12]. Primary prevention indications for
ICD therapy were deﬁned as (1) coronary artery disease (CAD),
non-sustained VT, LVEF o40%, and inducible sustained VT/VF;
(2) CAD, prior myocardial infarction, and LVEF o30%; or (3) other
(CAD, non-sustained VT, EF Z40%, and inducible VT/VF). Sec-
ondary prevention indications were deﬁned as (1) VF or cardiac
arrest without a transient or reversible cause, (2) spontaneous
sustained VT with structural heart disease, or (3) spontaneous
syncopal VT or syncope of unknown etiology and inducible sus-
tained VT/VF [13,14].
2.2.2. Health-related quality of life assessment
Health-related quality of life was assessed with the Japanese
version of the Medical Outcomes Study (MOS) Short Form 8-Item
Health Survey (SF-8) that evaluates both physical and mental
component summaries (PCS and MCS, respectively) [15]. Items are
answered on a 5- or 6-point Likert scale. The 8-domain scaled
scores range from 0 to 100, with 100 representing optimal health
and functioning. The SF-8 is divided into an 8-dimension health
proﬁle, including physical functioning (PF), role functioning-
physical (RP), bodily pain (BP), general health (GH), vitality (VT),
social functioning (SF), role functioning-emotional (RE), and
mental health (MH) [16].
2.2.3. Self-reported symptoms of anxiety
The state version of the State-Trait Anxiety Inventory (form
Japanese Y-1, STAI) is a 20-item self-reported measure. The STAI
was used to assess the presence of general symptoms of state and
trait anxiety [17]. This form of anxiety refers to a transient emo-
tional status, characterized by feelings of apprehension (i.e. wor-
ries and concerns) and tension as well as increased autonomic
nervous system activity. Items are scored on a four-point Likert
scale from 1 (not at all) to 4 (very much so). Scores range from 20
(low level of state anxiety) to 80 (high level of state anxiety). To
indicate clinically elevated levels of state anxiety, a cut-off of 444
has been used in previous studies [10]. Additionally, the cut-off
values of 40 in men and 42 in women for trait anxiety have been
used to dichotomize subjects into low and high levels of trait
anxiety [10,18].
2.2.4. Assessment of depression
Depressive symptoms over the prior week were assessed using
the Beck Depression Inventory (BDI) [19]. The BDI is a 21-item
interview, measuring the characteristic attitudes and symptoms of
depression. BDI has a maximum score of 63, and a score of 0–15
indicates being healthy, 16–30 indicates a minimal level of
depression, 31–46 indicates mild depression, and 47–63 indicates
severe depression. We dichotomized the presence of depression
by combining mild and severe depression into one group.
2.2.5. Evaluation of post-traumatic stress disorder (PTSD)
PTSD was assessed using the Impact of Event Scale-Revisited
(IES-R) [20]. The IES-R is a 22-item scale that is rated on a scale of
0 (not at all) to 4 (extremely), with respect to how distressing each
item has been during the past week. Scale scores are formed from
the three subscales, which reﬂect intrusion (8 items), avoidance (8
items), and hyperarousal (6 items), and show a high degree of
intercorrelation [21]. Good internal consistency and test-retest
values have been reported with the Japanese translation of the
IES-R [22]. A cut-off value of Z20 was used to indicate clinically
signiﬁcant levels of PTSD [23].
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The Worries About ICDs Scale (WAICD) is a modiﬁcation of the
26-item Index of Subjective Concerns for People with ICDs (ISCP-
ICD) that examines QOL issues associated with having an ICD, such
as driving restrictions, traveling problems, exercise limitations, or
job conditions after ICD implantation [10,24]. The items are mea-
sured on a 5-point Likert scale anchored at one end by 0 (not at all
true) and at the other end by 4 (extremely true) reﬂecting the
degree to which the respondent experiences each problem [24].
2.3. Statistical analyses
Data were presented as means7standard deviation for con-
tinuous variables and percentages for categorical variables. Dif-
ferences between groups stratiﬁed by ICD indication (primary vs.
secondary) were examined with the chi-square test (Fisher’s exact
test when appropriate) for nominal variables and are presented as
n (%). The Student’s t-test was used for independent samples
(Mann–Whitney U as alternative) with continuous variables, with
between group differences presented as mean (SD). Multivariable
analysis of variance (MANOVA) was performed to examine the
inﬂuence of ICD implantation indication on health-related QOL, as
measured by SF-8 subscales. Results from the SF-8 were adjusted
for older age, female gender, NYHA class III/IV, appropriate shocks,
inappropriate shocks, device-related complications, comorbidities,
and LVEF. MANOVA was also used to determine whether ICD
implantation indication was independently associated with trait
anxiety, state anxiety, depression, PTSD, and worries about the
ICD, adjusting older age, female gender, NYHA class III/IV, appro-
priate shock, inappropriate shock, device-related complications,
comorbidities, and LVEF. All the covariates entered in the adjusted
analysis were selected either on the basis of the literature or
results of univariable analysis. A p-value o0.05 was used to
indicate statistical signiﬁcance and all the tests were two-tailed.
All analyses were performed using Statistical Package for Social
Sciences (SPSS) software (Version 22.0, SPSS Inc., Chicago, IL, USA).Table 1
Demographic and clinical characteristics stratiﬁed by implantable cardioverter-
deﬁbrillator (ICD) implantation indication.
Primary
(n¼52)
Secondary
(n¼127)
p-Value
Demographics
Age, years (mean7SD) 62.0714.4 59.9716.4 0.393
Female patients, n (%) 10 (19.2) 24 (18.9) 0.959
Clinical factors
NYHA class III/IV, n (%) 3 (5.8) 17 (13.4) 0.142
LVEF, mean (SD) 54.2 (18.5) 53.7 (18.8) 0.879
Appropriate shock, n (%) 10 (19.2) 51 (40.5) 0.007
With syncope, n (%) 3 (5.8) 16 (12.7) 0.173
Without syncope, n (%) 8 (15.4) 43 (34.4) 0.011
Inappropriate shock, n (%) 13 (25.5) 33 (26.0) 0.946
Comorbidity, n (%) 32 (61.5) 77 (60.6) 0.910
Complication, n (%) 17 (32.7) 48 (37.8) 0.519
Duration of ICD therapy in
months, mean7SD
65.2746.1 73.3758.7 0.418
Shock frequency, mean7SD 0.771.5 1.271.3 0.037
Predominant cardiac diagnosis, n
(%)
0.908
Myocardial infarction 14 (26.9) 34 (26.8)
Dilated cardiomyopathy 6 (11.5) 16 (12.6)
Hypertrophic cardiomyopathy 11 (21.2) 14 (11.0)
Long QT syndrome 0 6 (4.7)
Brugada syndrome 19 (36.5) 18 (14.2)
Hypertensive heart diseases 0 3 (2.4)
Others 2 (3.8) 36 (28.4)
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction.3. Results
3.1. Patient characteristics
Patient characteristics for each group are displayed in Table 1.
The total group was comprised of 52 primary prevention ICD
recipients and 127 secondary prevention ICD recipients. Patients
with an ICD for secondary vs. primary prevention experienced
more appropriate shocks (40.5% vs. 19.2%, respectively, p¼0.007)
and therefore, the frequency of shocks was higher in secondary
prevention patients than in primary prevention patients (1.271.3
vs. 0.771.5, respectively, p¼0.037). Additionally, patients receiv-
ing ICD implantation for secondary prevention experienced more
appropriate shocks without syncope compared to patients
receiving ICD implantation for primary prevention (34.4% vs.
15.4%, respectively, p¼0.011). There were no differences in both
groups in age, gender, NYHA class III/IV, LVEF, comorbidities, and
device-related complications. Additionally, although the survey
was conducted once during outpatient clinic visits, there were no
signiﬁcant differences between primary and secondary prevention
groups in terms of the duration of ICD therapy (65.2746.1 months
vs. 73.3758.7 months, respectively, p¼0.418). The incidence of
inappropriate shocks was high in both groups (25.5% vs. 26.0% for
primary and secondary prevention groups, respectively). The high
incidence of atrial ﬁbrillation (AF, data not shown) in our study
population is one of the causes of vulnerability to inappropriate
shocks from an ICD[25].
3.2. Impact of ICD indication differences on anxiety, depression, post-
traumatic stress disorders, and worries about ICD
Descriptive characteristics for each ICD indication are presented
in Table 2. The mean score of trait anxiety and worries about ICD
were greater in primary prevention ICD recipients than in second-
ary prevention ICD recipients (41.7712.4 vs. 34.7712.3, p¼0.001
and 39.6718.0 vs. 30.0718.9, p¼0.002, respectively). Based on
Fig. 1, trait anxiety was more prevalent in primary prevention ICD
recipients than in secondary prevention ICD recipients (51.9% vs.
30.7%, respectively, p¼0.008). There were no differences between
the two groups regarding depression, state anxiety, and PTSD, in
either the mean score or the prevalence. Table 3 presents the
independent associates of the psychological endpoints, includingTable 2
Psychological characteristics and health-related quality of life scores stratiﬁed by
implantable cardioverter-deﬁbrillator (ICD) indication.
Primary (n¼52) Secondary
(n¼127)
p-Value
Psychological characteristics
Trait anxiety, mean (SD) 41.7 (12.4) 34.7 (12.3) 0.001
State anxiety, mean (SD) 40.7 (12.9) 38.1 (10.5) 0.203
Depression, mean (SD) 7.6 (9.5) 6.0 (7.0) 0.347
PTSD, mean (SD) 12.7 (19.4) 11.4 (15.1) 0.670
Worries about ICD, mean (SD) 39.6 (18.0) 30.0 (18.9) 0.002
Health-related quality of life scores
Physical functioning, mean
(SD)
45.3 (8.4) 45.4 (9.9) 0.905
Role physical functioning,
mean (SD)
46.5 (8.6) 46.2 (9.2) 0.854
Bodily pain, mean (SD) 52.5 (9.6) 54.0 (8.4) 0.368
General health, mean (SD) 44.4 (7.2) 45.5 (7.0) 0.367
Vitality, mean (SD) 48.2 (8.9) 52.4 (7.6) 0.004
Social functioning, mean (SD) 48.6 (8.4) 49.3 (8.5) 0.615
Role emotional functioning,
mean (SD)
45.4 (7.3) 46.0 (8.5) 0.686
Mental health, mean (SD) 48.3 (9.6) 49.3 (8.7) 0.538
PTSD, post-traumatic stress disorder.
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ICD. Of note, the primary prevention indication was associated with
trait anxiety and worries about the ICD. Additionally, female gender
was associated with depression, PTSD, and worries about ICD,
whereas appropriate shock was associated with PTSD.3.3. Impact of ICD indication differences on health-related QOL
Patients receiving ICD implantation for primary prevention had
an impaired health-related QOL on the vitality subscales of the SF-8Fig. 1. Prevalence of psychological disorders stratiﬁed by ICD indication. The pre-
valence of depression, post-traumatic stress disorder (PTSD), state anxiety, and trait
anxiety for both primary and secondary prevention indication is shown. The pre-
sence of the psychological disorders was determined using the cut-off value
determined for each questionnaire. n.s.¼not signiﬁcant.
Table 3
Independent associates of psychological characteristics scores.
State
anxiety
Trait
anxiety
Depression PTSD Worries
about ICD
F1,168 F1,168 F1,168 F1,168 F1,168
Primary prevention
indication
0.360 5.392n 1.885 1.373 4.712n
Older age 0.456 0.001 0.765 0.362 0.176
Female gender 0.257 0.009 5.313n 6.673n 5.666n
NYHA class III/IV 0.122 0.362 0.550 0.424 0.362
Appropriate shock 0.370 0.058 0.558 5.071n 0.004
Inappropriate shock 0.449 1.396 0.081 0.024 1.561
Complication 0.197 0.066 0.050 0.064 0.833
Comorbidity 0.008 0.147 0.074 0.506 0.086
LVEF 1.014 0.970 0.850 1.201 0.605
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; PTSD,
posttraumatic stress disorder; ICD, implantable cardioverter-deﬁbrillator.
n Po0.05.
Table 4
Independent associates of health-related quality of life scoresa.
SF-8 subscales PF RP BP
F1,162 F1,162 F1,162
Primary prevention indication 0.818 0.015 0.891
Older age 1.562 0.111 2.186
Female gender 7.664nn 3.880 7.520nn
NYHA class III/IV 1.859 1.193 5.775n
Appropriate shock 2.094 0.228 0.129
Inappropriate shock 0.768 0.005 0.050
Complication 1.002 0.082 0.031
Comorbidity 4.331n 1.787 0.959
LVEF 0.857 0.568 1.048
n Po0.05.
nn Po0.01.
a SF-8; PF, physical functioning; RP, role physical functioning; BP, bodily pain; GH, ge
mental health, NYHA, New York Heart Association; LVEF, left ventricular ejection fractio(Table 2). When adjusting for older age, female gender, NYHA class
III/IV, appropriate shocks, inappropriate shocks, device-related
complications, comorbidities, and LVEF, the primary prevention
indication was associated with an impaired health-related QOL on
the general health and vitality subscales (Table 4). Table 4 presents
all independent associates of health-related QOL. Of note, female
gender was associated with impaired QOL on physical functioning,
bodily pain, and general health subscales. Additionally, comorbid-
ities were associated with physical functioning subscales.4. Discussion
The results of this study showed that primary prevention ICD
recipients were more likely to be worried about their ICD, and they
reported high levels of trait anxiety. Additionally, although there
were no differences between the two groups in total health-related
QOL scores, ICD patients who received implantation for primary
prevention had an impaired QOL on the vitality subscales. No sta-
tistically signiﬁcant differences were found between primary and
secondary prevention ICD recipients on depression, PTSD, and state
anxiety. In the adjusted analysis, female gender was generally
associated with worse patient-centered outcomes, including
depression, PTSD, worries about ICD, and impaired health-related
QOL irrespective of ICD indication. Furthermore, appropriate shock
was also signiﬁcantly associated with increased PTSD.
Our study demonstrated higher trait anxiety and increased
worries about an ICD in ICD patients with a primary prevention
indication. In contrast, Bilge et al. did not ﬁnd any differences in
anxiety in primary and secondary prevention indication subgroups
[5]. Possible reasons for this discrepancy are the type of ques-
tionnaire and smaller sample size of the previous study. However,
both this study and the study by Bilge et al. found no differences in
depression between the two ICD indication groups. According to
the previous study, exposure to shocks may lead to an increased
risk of anxiety [26]. In this study we did not ﬁnd an independent
association between shocks and anxiety. However, the patients
with a primary prevention ICD experienced more shocks com-
pared to patients with a secondary prevention indication. A study
by Groeneveld et al. also showed that patients receiving a ICD for
secondary prevention had more shocks compared with a primary
indication, and shocks were associated with a lower QOL in pri-
mary prevention patients [9]. One possible explanation is that
secondary prevention patients, by deﬁnition, experienced a prior
cardiac arrest or ventricular arrhythmia. Therefore, secondary
prevention patients may have assessed their risk of SCD as being
higher, and thus found their ICDs to be potentially lifesaving
(particularly if the devices had actually delivered a shock). BesidesGH VT SF RE MH
F1,162 F1,162 F1,162 F1,162 F1,162
5.304n 9.168nn 1.385 1.242 3.639
1.052 0.410 0.130 0.665 0.223
5.901n 3.203 0.036 1.877 2.420
0.480 0.557 0.215 0.260 0.637
1.031 0.150 2.168 0.016 1.046
0.010 0.101 0.108 0.005 0.144
0.027 0.021 0.483 0.450 0.320
0.302 1.225 0.662 2.267 0.579
1.202 0.744 1.104 0.804 0.747
neral health; VT, vitality; SF, social functioning; RE, role emotional functioning; MH,
n.
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association with worries about an ICD; this is consistent with our
previous study [10]. Above all, behavioral interventions have
shown promise with respect to reducing distress such as anxiety
and worries in ICD patients [27].
Our ﬁndings show that primary prevention ICD recipients
experienced an impaired QOL on vitality subscales, which were
included in the physical health domain, compared to secondary
prevention ICD recipients. Similarly, Berg et al. also found that ICD
patients with a primary prevention indication had lower scores in
all subscales of QOL, and larger differences were found in physical
scores using other types of QOL questionnaires [11]. These results
are consistent with the fact that patients with an ICD for primary
prevention differ from those who receive the device for secondary
prevention, particularly because primary prevention patients may
fail to understand why they need the ICD [28]. Furthermore, they
may have fears concerning device malfunction and recall, and
device-associated complications including perforation, infection,
and perhaps of greatest importance, receipt of inappropriate shocks
[28,29]. On the other hand, Pedersen et al. reviewed the literature in
2009 and found ﬁve studies reporting patient-centered outcomes,
and none of them found an association between indication and
patient-centered outcomes such as QOL [8].
Taken together, this study suggests that although close mon-
itoring related to education and psychological interventions tar-
geting anxiety, depression, PTSD, worries about the ICD, and
health-related QOL are important to all ICD patients, recipients of a
primary prevention indication may have different needs following
ICD implantation compared to a secondary prevention indication.
A recent study of remote monitoring in ICD patients showed that a
clear understanding of ICD implantation was associated with a
higher acceptance of remote monitoring, which has been shown to
be related to patient safety and survival [30,31]. Remote mon-
itoring beneﬁts include more rapid clinical event detection and a
reduction in inappropriate shocks.
The results of this study should be interpreted with some
caution. First, this was a retrospective (not prospectively deﬁned)
subgroup analysis; the study was not originally designed to eval-
uate differences between ICD indication groups. Second, psycho-
logical evaluation was performed on patients only after ICD
implantation, and therefore a comparison with the preimplanta-
tion psychological status of the patients was not possible. In
addition, there were no follow-ups to evaluate score changes in
QOL and psychological functioning after any time intervals. Third,
information on psychological distress was obtained by a self-
report rather than a diagnostic interview, although all ques-
tionnaires were standardized and validated.
In conclusion, in this study, which mostly consisted of NYHA
class I and II subjects, patients with a primary prevention ICD were
more likely to experience anxiety, high levels of worry about their
ICD, and an impaired health-related QOL compared to patients
with a secondary prevention ICD. However, no differences were
found in depression or PTSD. In clinical practice, primary pre-
vention ICD recipients should be closely monitored. If warranted,
they should be offered a psychological intervention, because
anxiety and low QOL were predictors of mortality [11]. In the
future, further longitudinal and larger studies are needed to
examine these differences in psychological distress and QOL.Funding
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